Erin Reid

2.9k total citations
64 papers, 927 citations indexed

About

Erin Reid is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Erin Reid has authored 64 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 34 papers in Pathology and Forensic Medicine and 19 papers in Genetics. Recurrent topics in Erin Reid's work include Lymphoma Diagnosis and Treatment (34 papers), Viral-associated cancers and disorders (29 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Erin Reid is often cited by papers focused on Lymphoma Diagnosis and Treatment (34 papers), Viral-associated cancers and disorders (29 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Erin Reid collaborates with scholars based in United States, United Kingdom and Italy. Erin Reid's co-authors include Jeannette Y. Lee, Ariela Noy, Brad S. Kahl, Melhem Solh, Ethel Cesarman, Kirit M. Ardeshna, Mehdi Hamadani, Paolo F. Caimi, Mary Jo Lechowicz and Lee Ratner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Erin Reid

62 papers receiving 917 citations

Peers

Countries citing papers authored by Erin Reid

Since Specialization

Citations

This map shows the geographic impact of Erin Reid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Reid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Reid more than expected).

Fields of papers citing papers by Erin Reid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Reid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Reid. The network helps show where Erin Reid may publish in the future.

Co-authorship network of co-authors of Erin Reid

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Reid. A scholar is included among the top collaborators of Erin Reid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Reid. Erin Reid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Four years of mobile monitoring show that urban waste is the primary source of large methane emissions hotspots in Montreal, Canada 2025 ·Environmental Research Communications ·(unknown), Peter Douglas, (unknown), Erin Reid, Djordje Romanić, Felix Vogel, (unknown), (unknown), Yi Huang	1
2	Consensus recommendations on peripheral blood smear review: defining curricular standards and fellow competency 2023 ·Blood Advances ·(unknown), Reed E. Drews, Marc Zumberg, Leslie R. Ellis, Erin Reid, Aaron T. Gerds, Alfred Ian Lee, Gabriela Hobbs, (unknown), Jason A. Freed	2
3	AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma 2022 ·Clinical Cancer Research ·Erin Reid, Kelly A. Shimabukuro, Page C. Moore, Richard F. Ambinder, Jack D. Bui, (unknown), Otoniel Martı́nez-Maza, Dirk P. Dittmer, David M. Aboulafia, Elizabeth Y. Chiao, Toby Maurer, Robert A. Baiocchi, Ronald T. Mitsuyasu, William Wachsman	12
4	COVID-19 outcomes in patients with cancer and HIV: An analysis of the COVID-19 and Cancer Consortium (CCC19). 2022 ·Journal of Clinical Oncology ·Suki Subbiah, Jessica Y. Islam, Cassandra Hennessy, (unknown), Sharad Goyal, Diana Vilar‐Compte, (unknown), Talal El Zarif, Dimitrios Farmakiotis, Melissa Accordino, Francisco J. Hernandez‐Ilizaliturri, (unknown), Cecilia A. Castellano, Luca Paoluzzi, (unknown), Babar Bashir, Zhuoer Xie, Sanjay Mishra, Jeremy L. Warner, Erin Reid	1
5	Impact of Insurance Status on Outcomes in Individuals with AIDS-Defining Cancers 2021 ·AIDS Research and Human Retroviruses ·(unknown), Erin Reid	1
6	The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Paolo F. Caimi, Kirit M. Ardeshna, Erin Reid, Weiyun Z. Ai, Matthew A. Lunning, Jasmine Zain, Melhem Solh, Brad S. Kahl, Mehdi Hamadani	26
7	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma 2020 ·Blood ·Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl	122
8	Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial) 2020 ·Blood ·Juan Carlos Ramos, Joseph A. Sparano, Amy Chadburn, Erin Reid, Richard F. Ambinder, Eric R. Siegel, Page C. Moore, P Rubinstein, Christine M. Durand, Ethel Cesarman, David M. Aboulafia, Robert A. Baiocchi, Lee Ratner, Lawrence Kaplan, Adam A. Capoferri, Jeannette Y. Lee, Ronald T. Mitsuyasu, Ariela Noy	36
9	Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma 2019 ·Clinical Cancer Research ·Erin Reid, (unknown), Shelly Lensing, Dirk P. Dittmer, Richard F. Ambinder, Frank Maldarelli, Robert J. Gorelick, David M. Aboulafia, Ronald T. Mitsuyasu, Mark A. Dickson, William Wachsman	14
10	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Jay Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar, Shui He, Joseph Boni, Karin Havenith, Owen A. O’Connor	77
11	Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas 2018 ·Blood Advances ·Erin Reid, David J. Looney, Frank Maldarelli, Ariela Noy, David H. Henry, David M. Aboulafia, Juan Carlos Ramos, Joseph A. Sparano, Richard F. Ambinder, Jeannette Y. Lee, Ethel Cesarman, (unknown), Ronald T. Mitsuyasu, William Wachsman	9
12	AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL. 2018 ·Journal of Clinical Oncology ·Juan Carlos Ramos, Joseph A. Sparano, Page C. Moore, Ethel Cesarman, Erin Reid, P Rubinstein, Robert Harrington, Robert A. Baiocchi, (unknown), Lee Ratner, (unknown), Christine M. Durand, Richard F. Ambinder, Jeanette Y. Lee, Ronald T. Mitsuyasu, Ariela Noy	2
13	Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study 2018 ·Annals of Oncology ·Sven de Vos, L. J. Swinnen, Dee Dee Wang, Erin Reid, Nicole Fowler, Jaclyn Cordero, Martin Dunbar, Sari H. Enschede, Cathy E. Nolan, Adam M. Petrich, Jeremy A. Ross, Ahmed Hamed Salem, Maria Verdugo, Suresh Agarwal, Lang Zhou, Mark Kozloff, Loretta J. Nastoupil, Christopher R. Flowers	51
14	Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma 2017 ·Blood ·Brad S. Kahl, Mehdi Hamadani, Paolo F. Caimi, Carmelo Carlo‐Stella, Erin Reid, Jay Feingold, Kirit M. Ardeshna, John Radford, Melhem Solh, (unknown), Leonard T. Heffner, Shui He, Joseph Boni, Owen A. O’Connor	6
15	VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY 2017 ·Hematological Oncology ·L. J. Swinnen, Christopher R. Flowers, Dee Dee Wang, Erin Reid, Nathan Fowler, Jaclyn Cordero, Martin Dunbar, Sari H. Enschede, Cathy E. Nolan, Adam M. Petrich, Jeremy A. Ross, Ahmed Hamed Salem, (unknown), S. Wong, Lang Zhou, Mark Kozloff, Loretta J. Nastoupil, Sven de Vos	4
16	mTOR activity in AIDS-related diffuse large B-cell lymphoma 2017 ·PLoS ONE ·Sara H. Browne, Julio A. Díaz-Pérez, (unknown), Charles C. King, (unknown), Sonia Jain, Xiaoying Sun, Erin Reid, Scott R. VandenBerg, Huan‐You Wang	5
17	[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice 2016 ·Leukemia & lymphoma ·(unknown), Michelle Byrtek, Xiaolei Zhou, Jonathan W. Friedberg, Christopher R. Flowers, Andrew D. Zelenetz, Keith Dawson, Erin Reid	7
18	Short Communication: Lack of Occult HIV Infection Among Non-AIDS-Defining Cancer Patients in Three Academic Oncology Clinics in the United States 2013 ·AIDS Research and Human Retroviruses ·Sadeep Shrestha, Derek C. Johnson, Donna C. Porter, Erin Reid, (unknown), Sonia Napravnik, William C. Mathews, Joseph J. Eron, Michael S. Saag	4
19	HIV Co-receptor usage in HIV-related non-hodgkin's lymphoma 2012 ·Infectious Agents and Cancer ·Erin Reid, Sheldon Morris	1
20	Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease 2011 ·Current Drug Delivery ·Erin Reid, Ajay K. Nooka, (unknown), Mary Jo Lechowicz	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact